FGFR3 inhibitor compounds

The present invention provides compounds of the formula:, for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or ca...

Full description

Saved in:
Bibliographic Details
Main Authors WALLS, SHANE MICHAEL, HAZLITT, ROBERT ALAN, METCALF, ANDREW TERRANCE, URKALAN, KAVERI BALAN, KERCHER, TIMOTHY SCOTT, CONDROSKI, KEVIN RONALD, ABRAHAM, ADEDOYIN DAVID, BUME, DESTA DORO, DILGER, ANDREW KARL
Format Patent
LanguageChinese
English
Published 01.01.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides compounds of the formula:, for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.
Bibliography:Application Number: TW20220107515